Kura Oncology (KURA) Presents Data from HRAS Mutant Solid Tumors Phase 2 Trial at ESOC-9
- Wall St ticks up ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
November 4, 2016 7:30 AM EDTLA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the companys ongoing Phase 2 trial in HRAS mutant solid tumors at the 9th European Scientific Oncology Conference (ESOC-9) in Marbella, Spain. Antonio Gualberto, M.D., Ph.D., chief medical officer, delivered a presentation titled, Targeting the RAS-ERK Pathway.
Kura is currently evaluating tipifarnib, a farnesyl transferase inhibitor, as a potential treatment for patients with HRAS mutant solid tumors. In his presentation, Dr. Gualberto provided details on... More